HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

12.900

+0.3002.38%

Volume:4.71M

Turnover:60.96M

Market Cap:4.90B

PE:-9.99

High:13.470

Open:12.550

Low:12.330

Close:12.600

52wk High:46.100

52wk Low:12.100

Shares:380.07M

HK Float Shares:375.46M

Volume Ratio:1.57

T/O Rate:1.25%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.292

ROE:--

ROA:-27.71%

PB:12.19

PE(LYR):-9.99

PS:40660.96

Loading ...

Overview Company News Filings

TYK Medicines' Application for Lung Cancer Drug Accepted in China

MT Newswires Live

TYK Medicines, Inc. (2410) Announces NDA Acceptance for Asandeutertinib (TY-9591)

Bulletin Express

TYK MEDICINES-B's New Drug Application for TY-9591 Tablets Accepted by Regulatory Authority

Tyk Medicines Inc - Announces Nda Acceptance for Asandeutertinib

THOMSON REUTERS

TYK Medicines NDA for Asandeutertinib Accepted by China’s NMPA

TYK MEDICINES-B Shares Surge Nearly 5% in Afternoon Session as Key Drug Gains Priority Review Status

TYK Medicines (02410) Announces Monthly Securities Movements for January 2026

Bulletin Express

Hong Kong Stock Movement | TYK MEDICINES-B (02410) Surges Over 13% in Morning Session as Aimdotinib Mesylate Tablets Included in Priority Review List

TYK Medicines' Investigational Drug Included in China's Priority Review List

MT Newswires Live

TYK Medicines (Stock Code: 2410) Announces Priority Review Status for Asandeutertinib

Bulletin Express

TYK MEDICINES-B (02410) Has Its Investigational Class 1 New Drug, Aidosertinib Mesylate Tablets, Included in the CDE's Priority Review List

Tyk Medicines Inc - Inclusion of Asandeutertinib in List of Products for Priority Review by Center for Drug Evaluation of Nmpa China

THOMSON REUTERS

TYK Medicines' Asandeutertinib Included in NMPA Priority Review List

TYK Medicines Receives CSRC Filing Notice for H Share Full Circulation Application

TYK Medicines Receives Drug Manufacturing License from Zhejiang Authorities

TYK Medicines Gets CSRC Nod for Hong Kong Share Full Circulation

MT Newswires Live

BRIEF-TYK Medicines Granted Drug Manufacturing License By Drug Administration Of Zhejiang Province

TYK Medicines (2410) Receives CSRC Filing Notice for H Share Full Circulation

Bulletin Express

TYK MEDICINES-B (02410): China Securities Regulatory Commission Issues Filing Notice Regarding Company's Application for H-Share Full Circulation

TYK Medicines, Inc (Stock Code: 2410) Granted Drug Manufacturing License

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02410/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02410","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"TYK MEDICINES-B","latestPrice":12.9,"timestamp":1770365284005,"preClose":12.6,"halted":0,"volume":4705867,"delay":0,"changeRate":0.023809523809523867,"floatShares":375457818,"shares":380065818,"eps":-1.2915893391129727,"marketStatus":"Market Closed","change":0.3,"latestTime":"02-06 16:08:04","open":12.55,"high":13.47,"low":12.33,"amount":60963852,"amplitude":0.090476,"askPrice":12.95,"askSize":10000,"bidPrice":12.9,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-0.8698272530200504,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":7,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":12.6,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":1.5651235518300877,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","floatShares":375457818,"roa":"-27.71%","roe":"--","lyrEps":-1.291589,"volumeRatio":1.5651235518300877,"shares":380065818,"dividePrice":0,"high":13.47,"amplitude":0.090476,"preClose":12.6,"low":12.33,"week52Low":12.1,"pbRate":"12.19","psRate":"40660.96","week52High":46.1,"institutionHeld":0,"latestPrice":12.9,"committee":0.166667,"eps":-1.2915893391129727,"divideRate":0,"volume":4705867,"delay":0,"ttmEps":-0.8698272530200504,"open":12.55,"prevYearClose":13.11,"prevWeekClose":12.65,"prevMonthClose":12.65,"prevQuarterClose":13.11,"fiveDayClose":12.65,"twentyDayClose":14.3,"sixtyDayClose":13.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02410\",params:#limit:5,,,undefined,":[{"date":"2025-08-31","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756603800000,"name":null,"time":"","dateTimestamp":1756569600000,"actualEps":null},{"date":"2025-03-27","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743039000000,"name":null,"time":"","dateTimestamp":1743004800000,"actualEps":null},{"date":"2024-08-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724981400000,"name":null,"time":"","dateTimestamp":1724947200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02410\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02410\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1747324800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02410\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02410","date":"2026-02-05","current":-14.830531,"percent":0.911602,"low":-45.171338,"twenty":-24.953295,"median":-18.947946,"eighty":-16.15987,"high":-10.104382,"avg":-20.897569,"sd":6.147633,"marketCap":4788829306},"quantilePoints":[{"date":"2024-08-23","current":-18.036629,"twenty":-16.647141,"median":-14.72623,"eighty":-12.008468,"marketCap":8010053668},{"date":"2024-08-30","current":-17.916348,"twenty":-18.108709,"median":-17.490261,"eighty":-14.277882,"marketCap":8010053668},{"date":"2024-09-06","current":-22.38992,"twenty":-20.387629,"median":-17.957821,"eighty":-15.985061,"marketCap":10531737231},{"date":"2024-09-13","current":-25.215246,"twenty":-24.52304,"median":-18.767123,"eighty":-16.911292,"marketCap":11829662594},{"date":"2024-09-20","current":-22.432724,"twenty":-24.518581,"median":-20.496807,"eighty":-17.208183,"marketCap":10587362603},{"date":"2024-09-27","current":-24.719835,"twenty":-24.497927,"median":-22.38992,"eighty":-17.671485,"marketCap":11736953639},{"date":"2024-10-04","current":-24.95032,"twenty":-24.87878,"median":-23.321155,"eighty":-17.932937,"marketCap":11792579012},{"date":"2024-10-10","current":-25.38933,"twenty":-24.941363,"median":-23.362473,"eighty":-17.973583,"marketCap":11922371548},{"date":"2024-10-18","current":-26.355956,"twenty":-25.311733,"median":-23.798709,"eighty":-18.108709,"marketCap":12311749157},{"date":"2024-10-25","current":-24.571342,"twenty":-25.374683,"median":-24.122054,"eighty":-18.545067,"marketCap":11477368567},{"date":"2024-11-01","current":-18.445843,"twenty":-25.311733,"median":-23.998666,"eighty":-18.584118,"marketCap":8621932768},{"date":"2024-11-08","current":-20.323115,"twenty":-25.278482,"median":-23.623818,"eighty":-17.973583,"marketCap":9456313359},{"date":"2024-11-15","current":-19.45318,"twenty":-25.171449,"median":-23.425489,"eighty":-18.108709,"marketCap":8955685004},{"date":"2024-11-22","current":-24.620137,"twenty":-24.988066,"median":-23.362473,"eighty":-18.406793,"marketCap":11329034239},{"date":"2024-11-29","current":-31.047836,"twenty":-25.311733,"median":-23.554037,"eighty":-18.584118,"marketCap":14277178993},{"date":"2024-12-06","current":-34.758675,"twenty":-25.786797,"median":-23.737743,"eighty":-19.168188,"marketCap":15945940174},{"date":"2024-12-13","current":-35.961329,"twenty":-26.0415,"median":-24.070769,"eighty":-19.324298,"marketCap":16465110319},{"date":"2024-12-20","current":-44.500897,"twenty":-30.298107,"median":-24.44033,"eighty":-19.494791,"marketCap":20284719244},{"date":"2024-12-27","current":-43.273475,"twenty":-31.455257,"median":-24.553474,"eighty":-19.619623,"marketCap":19709923726},{"date":"2025-01-03","current":-39.042242,"twenty":-33.760908,"median":-24.669986,"eighty":-19.709581,"marketCap":17800119264},{"date":"2025-01-10","current":-16.73771,"twenty":-34.083555,"median":-24.719835,"eighty":-19.709581,"marketCap":7602134269},{"date":"2025-01-17","current":-16.071561,"twenty":-33.760908,"median":-24.553474,"eighty":-18.860667,"marketCap":7305465614},{"date":"2025-01-24","current":-20.268382,"twenty":-32.413923,"median":-24.349989,"eighty":-19.230133,"marketCap":9270895450},{"date":"2025-01-28","current":-18.549699,"twenty":-31.591026,"median":-24.122054,"eighty":-18.549699,"marketCap":8529223814},{"date":"2025-02-07","current":-17.965815,"twenty":-31.472067,"median":-23.871541,"eighty":-18.275892,"marketCap":8214013368},{"date":"2025-02-14","current":-19.878813,"twenty":-31.451054,"median":-23.623818,"eighty":-18.275892,"marketCap":9066935750},{"date":"2025-02-21","current":-25.066745,"twenty":-31.047836,"median":-23.789321,"eighty":-18.32609,"marketCap":11495910358},{"date":"2025-02-28","current":-26.244856,"twenty":-30.411824,"median":-23.765234,"eighty":-18.39703,"marketCap":11996538712},{"date":"2025-03-07","current":-24.725844,"twenty":-30.135297,"median":-23.927628,"eighty":-18.445843,"marketCap":11347576030},{"date":"2025-03-14","current":-23.101371,"twenty":-29.84324,"median":-23.977848,"eighty":-18.549699,"marketCap":10605904394},{"date":"2025-03-21","current":-22.868028,"twenty":-28.789228,"median":-23.789321,"eighty":-18.691799,"marketCap":10494653649},{"date":"2025-03-28","current":-28.703724,"twenty":-28.703724,"median":-23.977848,"eighty":-19.110968,"marketCap":13146129748},{"date":"2025-04-03","current":-29.204856,"twenty":-29.744706,"median":-24.122054,"eighty":-19.131966,"marketCap":12070705875},{"date":"2025-04-11","current":-24.387234,"twenty":-29.307899,"median":-24.067881,"eighty":-19.145106,"marketCap":10012567086},{"date":"2025-04-17","current":-24.599189,"twenty":-28.955479,"median":-24.067881,"eighty":-19.224594,"marketCap":10123817831},{"date":"2025-04-25","current":-24.758022,"twenty":-28.755026,"median":-24.236021,"eighty":-19.282593,"marketCap":10197984995},{"date":"2025-05-02","current":-30.859428,"twenty":-28.772127,"median":-24.368612,"eighty":-19.308976,"marketCap":12738210348},{"date":"2025-05-09","current":-26.222368,"twenty":-28.789228,"median":-24.487968,"eighty":-19.376573,"marketCap":11477368567},{"date":"2025-05-16","current":-19.875071,"twenty":-28.703724,"median":-24.44033,"eighty":-19.45318,"marketCap":8770267095},{"date":"2025-05-23","current":-18.391406,"twenty":-28.460584,"median":-24.320388,"eighty":-19.147078,"marketCap":8139846205},{"date":"2025-05-30","current":-16.767615,"twenty":-28.328721,"median":-24.116277,"eighty":-18.777931,"marketCap":7453799941},{"date":"2025-06-06","current":-19.720458,"twenty":-27.077703,"median":-23.93026,"eighty":-18.847277,"marketCap":8788808886},{"date":"2025-06-13","current":-16.18601,"twenty":-26.697665,"median":-23.850097,"eighty":-18.709822,"marketCap":7216465018},{"date":"2025-06-20","current":-14.05098,"twenty":-26.664525,"median":-23.778892,"eighty":-18.426653,"marketCap":6252291891},{"date":"2025-06-27","current":-16.3221,"twenty":-26.630078,"median":-23.66211,"eighty":-18.32609,"marketCap":7283215465},{"date":"2025-07-04","current":-17.493079,"twenty":-26.41078,"median":-23.623818,"eighty":-18.194509,"marketCap":7806093968},{"date":"2025-07-11","current":-16.487526,"twenty":-26.267076,"median":-23.430941,"eighty":-17.964216,"marketCap":7349965912},{"date":"2025-07-18","current":-15.867745,"twenty":-26.226866,"median":-23.321155,"eighty":-17.866761,"marketCap":7068130691},{"date":"2025-07-25","current":-16.407488,"twenty":-26.143659,"median":-23.070409,"eighty":-17.335488,"marketCap":7335132480},{"date":"2025-08-01","current":-14.539711,"twenty":-26.072617,"median":-22.868028,"eighty":-17.325642,"marketCap":6459959949},{"date":"2025-08-08","current":-15.316665,"twenty":-25.987382,"median":-22.563641,"eighty":-17.04089,"marketCap":6822181433},{"date":"2025-08-15","current":-17.450454,"twenty":-25.968574,"median":-22.406203,"eighty":-16.915178,"marketCap":7760944003},{"date":"2025-08-22","current":-13.484776,"twenty":-25.95357,"median":-22.354126,"eighty":-16.718364,"marketCap":5978435317},{"date":"2025-08-29","current":-12.516323,"twenty":-25.925655,"median":-21.46252,"eighty":-16.486483,"marketCap":5575565550},{"date":"2025-09-05","current":-19.23268,"twenty":-25.919389,"median":-21.226743,"eighty":-16.486483,"marketCap":5883418862},{"date":"2025-09-12","current":-18.156363,"twenty":-25.850806,"median":-20.678772,"eighty":-16.541494,"marketCap":5564163575},{"date":"2025-09-19","current":-18.839434,"twenty":-25.807696,"median":-20.500943,"eighty":-16.56352,"marketCap":5769399117},{"date":"2025-09-26","current":-19.348832,"twenty":-25.743581,"median":-20.268382,"eighty":-16.654406,"marketCap":5910023469},{"date":"2025-10-03","current":-22.468168,"twenty":-25.650075,"median":-20.314843,"eighty":-16.707921,"marketCap":6879191305},{"date":"2025-10-10","current":-19.927643,"twenty":-25.596841,"median":-20.323115,"eighty":-16.732368,"marketCap":6092455062},{"date":"2025-10-17","current":-19.134493,"twenty":-25.519561,"median":-20.155539,"eighty":-16.749672,"marketCap":5845412280},{"date":"2025-10-24","current":-17.635142,"twenty":-25.404318,"median":-19.980008,"eighty":-16.781291,"marketCap":5389333299},{"date":"2025-10-31","current":-19.024541,"twenty":-25.400784,"median":-19.927643,"eighty":-16.830147,"marketCap":5822608331},{"date":"2025-11-07","current":-17.694439,"twenty":-25.37593,"median":-19.869193,"eighty":-16.945559,"marketCap":5412137248},{"date":"2025-11-14","current":-17.099248,"twenty":-25.321084,"median":-19.741813,"eighty":-16.951188,"marketCap":5244908288},{"date":"2025-11-21","current":-15.19815,"twenty":-25.311733,"median":-19.694587,"eighty":-16.919035,"marketCap":4659606928},{"date":"2025-11-28","current":-16.711808,"twenty":-25.293455,"median":-19.641679,"eighty":-16.730587,"marketCap":5142290517},{"date":"2025-12-05","current":-17.262657,"twenty":-25.275139,"median":-19.635782,"eighty":-16.587841,"marketCap":5320921452},{"date":"2025-12-12","current":-16.160016,"twenty":-25.213434,"median":-19.544821,"eighty":-16.497144,"marketCap":4990264190},{"date":"2025-12-19","current":-16.355316,"twenty":-25.19336,"median":-19.414876,"eighty":-16.454475,"marketCap":5062476695},{"date":"2025-12-24","current":-15.692499,"twenty":-25.154877,"median":-19.348832,"eighty":-16.406101,"marketCap":4872443786},{"date":"2026-01-02","current":-15.765099,"twenty":-25.10227,"median":-19.292077,"eighty":-16.35327,"marketCap":4914251026},{"date":"2026-01-09","current":-17.392186,"twenty":-25.070347,"median":-19.235279,"eighty":-16.345574,"marketCap":5434941197},{"date":"2026-01-16","current":-16.438751,"twenty":-25.06473,"median":-19.137216,"eighty":-16.35327,"marketCap":5153692492},{"date":"2026-01-23","current":-15.75073,"twenty":-25.023112,"median":-19.120814,"eighty":-16.314941,"marketCap":4933254317},{"date":"2026-01-30","current":-15.280433,"twenty":-24.971672,"median":-19.022068,"eighty":-16.22453,"marketCap":4807832597},{"date":"2026-02-05","current":-15.18153,"twenty":-24.953295,"median":-18.947946,"eighty":-16.15987,"marketCap":4788829306}],"updateTime":1770419871142},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02410\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609569027","title":"TYK Medicines' Application for Lung Cancer Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2609569027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609569027?lang=en_us&edition=fundamental","pubTime":"2026-02-06 18:00","pubTimestamp":1770372036,"startTime":"0","endTime":"0","summary":"TYK Medicines'  new drug application for Asandeutertinib was accepted by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The acceptance is for the indication of first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02410","MDCO","BK1161"],"gpt_icon":0},{"id":"1170178089","title":"TYK Medicines, Inc. (2410) Announces NDA Acceptance for Asandeutertinib (TY-9591)","url":"https://stock-news.laohu8.com/highlight/detail?id=1170178089","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170178089?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:22","pubTimestamp":1770369748,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (Stock Code: 2410) announced that the National Medical Products Administration’s Center for Drug Evaluation has accepted its New Drug Application for Asandeutertinib (TY-9591)....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1168835529","title":"TYK MEDICINES-B's New Drug Application for TY-9591 Tablets Accepted by Regulatory Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1168835529","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168835529?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:06","pubTimestamp":1770368786,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced that the New Drug Application (NDA) for its investigational Class 1 new drug, TY-9591 tablets (Edotinib Mesylate Tablets), has been accepted for review by the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1161","TY","BK1574","BK1515","02410","09939"],"gpt_icon":0},{"id":"2609565121","title":"Tyk Medicines Inc - Announces Nda Acceptance for Asandeutertinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2609565121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609565121?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:00","pubTimestamp":1770368453,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z201R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02410","BK1161"],"gpt_icon":0},{"id":"2609406565","title":"TYK Medicines NDA for Asandeutertinib Accepted by China’s NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2609406565","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609406565?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:00","pubTimestamp":1770368447,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. announced that its New Drug Application  for Asandeutertinib  has been accepted by the Center for Drug Evaluation of the National Medical Products Administration  in China. The application is for the registration of Asandeutertinib as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer  harboring EGFR exon 19 deletion or exon 21  substitution mutations, including those with central nervous system metastases. The acceptance follows a review under Article 32 of the Administrative License Law of the People’s Republic of China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL7MQWqB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"1102746798","title":"TYK MEDICINES-B Shares Surge Nearly 5% in Afternoon Session as Key Drug Gains Priority Review Status","url":"https://stock-news.laohu8.com/highlight/detail?id=1102746798","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102746798?lang=en_us&edition=fundamental","pubTime":"2026-02-06 14:26","pubTimestamp":1770359177,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) experienced a notable increase of nearly 5% during afternoon trading. At the time of writing, the stock was up 3.65%, trading at HK$13.06, with a turnover of HK$28.91 million....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","09939","BK1515","BK1574","VT","BK1161","159938","VXUS","BK4585","02410"],"gpt_icon":0},{"id":"1144504941","title":"TYK Medicines (02410) Announces Monthly Securities Movements for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1144504941","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144504941?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:45","pubTimestamp":1770111912,"startTime":"0","endTime":"0","summary":"TYK Medicines (02410) submitted its Monthly Return for the period ended January 31, 2026, reporting no changes in the registered share capital. The total authorized/registered share capital remained...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1199886224","title":"Hong Kong Stock Movement | TYK MEDICINES-B (02410) Surges Over 13% in Morning Session as Aimdotinib Mesylate Tablets Included in Priority Review List","url":"https://stock-news.laohu8.com/highlight/detail?id=1199886224","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199886224?lang=en_us&edition=fundamental","pubTime":"2026-01-30 09:52","pubTimestamp":1769737939,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) surged more than 13% during the morning session. As of the time of writing, the stock was up 8.94%, trading at HK$13.52, with a turnover of HK$40.70 million. The company...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","09939","159938","BK1161","BK1515","BK4585","VT","BK4588","BK1574"],"gpt_icon":0},{"id":"2607008467","title":"TYK Medicines' Investigational Drug Included in China's Priority Review List","url":"https://stock-news.laohu8.com/highlight/detail?id=2607008467","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607008467?lang=en_us&edition=fundamental","pubTime":"2026-01-29 17:46","pubTimestamp":1769679988,"startTime":"0","endTime":"0","summary":"TYK Medicines (HKG:2410) said its investigational drug TY-9591 was included in China's priority review list, according to a Hong Kong bourse filing Thursday.The drug is being studied as a treatment for lung cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","MDCO","02410"],"gpt_icon":0},{"id":"1178307660","title":"TYK Medicines (Stock Code: 2410) Announces Priority Review Status for Asandeutertinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1178307660","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178307660?lang=en_us&edition=fundamental","pubTime":"2026-01-29 17:45","pubTimestamp":1769679939,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc (Stock Code: 2410) has reported that its investigational Class 1 new drug, Asandeutertinib (TY-9591), has been listed for priority review by the Center for Drug Evaluation (CDE)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1181975144","title":"TYK MEDICINES-B (02410) Has Its Investigational Class 1 New Drug, Aidosertinib Mesylate Tablets, Included in the CDE's Priority Review List","url":"https://stock-news.laohu8.com/highlight/detail?id=1181975144","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181975144?lang=en_us&edition=fundamental","pubTime":"2026-01-29 17:10","pubTimestamp":1769677818,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that its investigational Class 1 new drug, Aidosertinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种 list by the Center for Drug...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1574","09939","BK1161","02410"],"gpt_icon":0},{"id":"2607702545","title":"Tyk Medicines Inc - Inclusion of Asandeutertinib in List of Products for Priority Review by Center for Drug Evaluation of Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2607702545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607702545?lang=en_us&edition=fundamental","pubTime":"2026-01-29 17:07","pubTimestamp":1769677665,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU0JT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02410"],"gpt_icon":0},{"id":"2607541702","title":"TYK Medicines' Asandeutertinib Included in NMPA Priority Review List","url":"https://stock-news.laohu8.com/highlight/detail?id=2607541702","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607541702?lang=en_us&edition=fundamental","pubTime":"2026-01-29 17:07","pubTimestamp":1769677643,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. announced that its investigational Class 1 new drug, Asandeutertinib , has been included in the List of Products for Priority Review by the Center for Drug Evaluation of the National Medical Products Administration  in China. The drug is proposed as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer  harboring EGFR exon 19 deletion or exon 21  substitution mutation, including those with central nervous system metastases. The priority review status was granted in accordance with relevant regulatory requirements under the Administration Measures for Drug Registration and other related guidelines. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDLbYSJjV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"2606291412","title":"TYK Medicines Receives CSRC Filing Notice for H Share Full Circulation Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2606291412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606291412?lang=en_us&edition=fundamental","pubTime":"2026-01-26 14:57","pubTimestamp":1769410676,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. announced that it has received a filing notice from the China Securities Regulatory Commission  regarding its application for H Share Full Circulation. The filing is valid for 12 months from the date of approval by the CSRC. The company stated that the details of the implementation plan for the H Share Full Circulation have not yet been finalized and will be disclosed in accordance with regulatory requirements as progress is made. The H Share Full Circulation remains subject to further procedures required by the Hong Kong Stock Exchange and other regulatory authorities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL10lTyH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"2606291947","title":"TYK Medicines Receives Drug Manufacturing License from Zhejiang Authorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2606291947","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606291947?lang=en_us&edition=fundamental","pubTime":"2026-01-26 14:49","pubTimestamp":1769410176,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. has announced that it has been granted a Drug Manufacturing License  by the Drug Administration of Zhejiang Province. The license is valid until January 22, 2031, and is expected to support the company's capacity and market expansion, laying the groundwork for subsequent commercial production. The company noted that there is no assurance the relevant product will ultimately be successfully developed and marketed. No other beneficiary organizations were mentioned in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 23, 2026, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL3x6wqV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"2606829345","title":"TYK Medicines Gets CSRC Nod for Hong Kong Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2606829345","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606829345?lang=en_us&edition=fundamental","pubTime":"2026-01-26 12:06","pubTimestamp":1769400403,"startTime":"0","endTime":"0","summary":"TYK Medicines  said the China Securities Regulatory Commission has issued a filing notice approving its Hong Kong-listed shares' full circulation application, according to a Jan. 23 Hong Kong bourse filing.Shares of the company were down nearly 2% in late-morning trade on Monday.The approval covers the conversion of 4.6 million domestic shares held by one shareholder into 4.6 million Hong Kong-listed shares.Subject to listing approval from the Hong Kong Stock Exchange, the converted shares will be listed and traded on the main board.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","02410","BK1161"],"gpt_icon":0},{"id":"2605740907","title":"BRIEF-TYK Medicines Granted Drug Manufacturing License By Drug Administration Of Zhejiang Province","url":"https://stock-news.laohu8.com/highlight/detail?id=2605740907","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605740907?lang=en_us&edition=fundamental","pubTime":"2026-01-23 23:28","pubTimestamp":1769182088,"startTime":"0","endTime":"0","summary":"BRIEF-TYK Medicines Granted Drug Manufacturing License By Drug Administration Of Zhejiang ProvinceJan 23 (Reuters) - TYK Medicines Inc 2410.HK:GRANTED DRUG MANUFACTURING LICENSE BY DRUG ADMINISTRATION OF ZHEJIANG PROVINCEFurther company coverage: 2410.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO09V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"gpt_icon":0},{"id":"1164449304","title":"TYK Medicines (2410) Receives CSRC Filing Notice for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1164449304","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164449304?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:04","pubTimestamp":1769169846,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (Stock Code: 2410) has announced that the China Securities Regulatory Commission (CSRC) recently issued a filing notice in relation to its H Share Full Circulation application....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1177022278","title":"TYK MEDICINES-B (02410): China Securities Regulatory Commission Issues Filing Notice Regarding Company's Application for H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1177022278","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177022278?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:50","pubTimestamp":1769169032,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that the China Securities Regulatory Commission (CSRC) has recently issued a filing notice to the company concerning the H-share full circulation plan. According to...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","159938","09939","BK1574","BK1161","BK1515"],"gpt_icon":0},{"id":"1156381147","title":"TYK Medicines, Inc (Stock Code: 2410) Granted Drug Manufacturing License","url":"https://stock-news.laohu8.com/highlight/detail?id=1156381147","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156381147?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:44","pubTimestamp":1769168676,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (Stock Code: 2410) announced that it has been granted the Drug Manufacturing License by the Drug Administration of Zhejiang Province. According to the announcement,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}]}}